Tag: Cardiovascular devices
Reading a clearance summary without overreading the clearance
A clearance summary can inform an evidence budget or predicate shortlist. Its value depends on separating what the record establishes from what it leaves unanswered.
What determines the EU risk class of cardiovascular software?
EU software classification connects intended clinical use to the consequences of erroneous information. That reasoning also informs evidence, budget and conformity assessment.
Clinical evidence planning starts with the intended use
A well-run study can still leave a device claim unanswered. Map intended use to population, outcomes and evidence gaps before deciding which clinical work to commission.
What do the EU’s new notified-body timelines mean for your launch plan?
The EU’s new notified-body rules define assessment milestones, but launch timing still depends on evidence readiness, parallel work and interruptions. Learn what the clocks actually measure.
Singapore permits two change notifications; but the release sequence still matters
Two change-notification applications can create flexibility in Singapore. Their value depends on dependencies, affected listings and implementation conditions.
Australia’s UDI rollout makes stock status a market-access decision
Australia’s UDI rollout can treat batches of the same device differently. Manufacturing, labelling and supply history help determine the applicable obligations.
ECG-MR’s clearance shows the value and boundaries of a PCCP
A cleared ECG-MR change plan offers a practical example of connecting future model and compatibility updates to the evidence needed before release.
Design transfer for connected cardiovascular devices
A working development unit does not establish production readiness. Design transfer makes hardware, software configuration and acceptance decisions reproducible beyond the engineering team.
Bench, analytical and clinical evidence in a cardiovascular program
A cardiovascular device company faces complex decisions despite successful engineering results. Testing outcomes need clarity regarding their clinical relevance versus technical validation. Understanding distinctions between physical endurance, measurement accuracy, and clinical impact is crucial. Unresolved questions inform the necessary next steps for further investigation, highlighting the importance of targeted studies over generalized conclusions.